EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas

Hiroyuki Suzuki iD, Nohara Goto, Tomohiro Tanaka, Tsunenori Ouchida, Mika K Kaneko, Yukinari Kato iD

Antibodies · 04.07.2023 · 12 (3) · 45

DOI: 10.3390/antib12030045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibodies, online erschienen am 04.07.2023. Verfasst von Hiroyuki Suzuki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide. GC with peritoneal metastasis exhibits a poor prognosis due to the lack of effective therapy. A comprehensive analysis of malignant ascites identified the genomic alterations and significant amplifications of cancer driver genes, including CD44. CD44 and its splicing variants are overexpressed in tumors, and play crucial roles in the acquisition of invasiveness, stemness, and resistance to treatments. Therefore, the development of CD44-targeted monoclonal antibodies (mAbs) is important for GC diagnosis and therapy. In this study, we immunized mice with CD44v3–10-overexpressed PANC-1 cells and established several dozens of clones that produce anti-CD44v3–10 mAbs. One of the clones (C44Mab-94; IgG1, kappa) recognized the variant-8-encoded region and peptide, indicating that C44Mab-94 is a specific mAb for CD44v8. Furthermore, C44Mab-94 could recognize CHO/CD44v3–10 cells, oral squamous cell carcinoma cell line (HSC-3), or GC cell lines (MKN45 and NUGC-4) in flow cytometric analyses. C44Mab-94 could detect the exogenous CD44v3–10 and endogenous CD44v8 in western blotting and stained the formalin-fixed paraffin-embedded gastric cancer cells. These results indicate that C44Mab-94 is useful for detecting CD44v8 in a variety of experimental methods and is expected to become usefully applied to GC diagnosis and therapy.

Schlagwörter

Stichwörter der Autor:innen

CD44 variant 8flow cytometrygastric cancerimmunohistochemistrymonoclonal antibody

Autor:innen und Institutionen

  • Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.

ORCID-Profile: Hiroyuki Suzuki, Yukinari Kato

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Suzuki, H., Goto, N., Tanaka, T., Ouchida, T., Kaneko, M. K., & Kato, Y. (2023). Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas. Antibodies, 12(3), 45. https://doi.org/10.3390/antib12030045

Vancouver

Suzuki H, Goto N, Tanaka T, Ouchida T, Kaneko MK, Kato Y. Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas. Antibodies. 2023;12(3):45. doi:10.3390/antib12030045

BibTeX
@article{Suzuki2023,
  author = {Suzuki, Hiroyuki and Goto, Nohara and Tanaka, Tomohiro and Ouchida, Tsunenori and Kaneko, Mika K and Kato, Yukinari},
  title = {Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas},
  journal = {Antibodies},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {45},
  doi = {10.3390/antib12030045}
}
Kostenlos starten →